Comparative Pharmacology
Head-to-head clinical analysis: FLUCONAZOLE versus POSFREA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUCONAZOLE versus POSFREA.
Fluconazole vs POSFREA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluconazole is a triazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane.
POSFREA is a carbapenem-class antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death.
200-400 mg orally or intravenously once daily. For candidemia and other invasive Candida infections, loading dose of 800 mg (12 mg/kg) on day 1, then 400 mg (6 mg/kg) daily.
IV 4 mg/kg once daily; infused over 90 minutes.
None Documented
None Documented
Terminal elimination half-life ~30 hours (range 20-50 h) in patients with normal renal function; prolonged in renal impairment (up to 98 h in CrCl <20 mL/min). This long half-life supports once-daily dosing and allows loading dose administration.
Clinical Note
moderateMethoxsalen + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Methoxsalen."
Clinical Note
moderateCyclophosphamide + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Cyclophosphamide."
Clinical Note
moderatePaclitaxel + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Paclitaxel."
Clinical Note
moderateDocetaxel + Fluconazole
12 hours (range 10-14) in healthy adults; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min).
Renal: approximately 80% as unchanged drug; biliary/fecal: ~11% as metabolites and unchanged drug.
Renal (95%) as unchanged drug; biliary/fecal (5%).
Category C
Category C
Azole Antifungal
Azole Antifungal
"The metabolism of Fluconazole can be decreased when combined with Docetaxel."